Skip to content
Menu

Intensity Therapeutics, Inc. INTS

Full chart Compare
Set alert

Price alert · INTS

All alert types
2.47 USD -0.07 (-2.76%)

As ofNov 20, 2026, 2:05 PM EST

2.28 Day range 2.48
2.28 52-week range 15.00
YTD
-75.90%
1 year
-74.00%

5D +0.10 (+3.37%)

33.203.40TueWedThuFriMon3.07
Market cap
8.15M
EPS (ttm)
-3.48
Shares out
15.10M
Forward P/E
-1.66
YTD return
-75.90%
1-year return
-74.00%
50-day average
2.90
200-day average
4.10
Volume
50.20K
Avg volume
21.82K
Open
2.39
Previous close
2.54
Day's range
2.28 – 2.48
52-week range
2.28 – 15.00
Analysts
Strong Buy
Price target
10.00 (+304.9%)

Key statistics

Enterprise value
37.55M
Price / book
2.04
Free cash flow
9.66M
Total cash
6.32M
Total debt
151.00K
Return on equity
-147.23%
Short % of float
0.48%

Fundamental scorecard

5 of 25 checks passed on INTS’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
INTS Revenue — quarterly 0
INTS Net income — quarterly -3.54M
INTS EPS — quarterly -1.09

Earnings

INTS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.27-0.25+0.02+7.41%
Aug 8, 2024Jun 1, 20240.00———
Aug 8, 2024Jun 1, 20240.00-0.36——
Mar 14, 2024Dec 1, 20230.00———
Nov 13, 2023Sep 1, 20230.00-0.17——
Nov 13, 2023Sep 1, 20230.00———

Upgrades / downgrades

INTS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 21, 2024HC Wainwright & Co.reitBuyBuy
Oct 31, 2024HC Wainwright & Co.init—Buy
Jul 11, 2024BenchmarkreitSpeculative BuySpeculative Buy
May 16, 2024BenchmarkreitSpeculative BuySpeculative Buy
Mar 21, 2024BenchmarkreitSpeculative BuySpeculative Buy
Nov 14, 2023BenchmarkreitSpeculative BuySpeculative Buy

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on INTS — it syncs with the Stock Master app.

Insider holders

INTS insider holders
InsiderRelationLatest transactionDateShares held
WESOLOWSKI JOHN CPAOfficerConversion of Exercise of derivative securityJun 4, 20246,691

Institution ownership

INTS institution ownership
Holder% heldSharesValueReported
Sapient Capital LLC 6.69%1,010,7531.98MSep 29, 2024
Vanguard Group Inc1.38%208,886408.85KSep 29, 2024
Brown Advisory Inc.0.98%148,109289.89KSep 29, 2024
Geode Capital Management, LLC0.43%64,349125.95KSep 29, 2024
Sigma Planning Corp0.32%47,74493.45KSep 29, 2024
Mesirow Financial Investment Management, Inc.0.29%44,17786.47KSep 29, 2024

Fund ownership

INTS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.11%168,299329.41KSep 29, 2024
Vanguard Extended Market Index Fund0.27%40,58779.44KSep 29, 2024
Fidelity Extended Market Index Fund0.23%34,52267.57KOct 30, 2024
iShares Micro Cap ETF0.13%20,12339.39KOct 30, 2024
Fidelity Total Market Index Fund0.06%9,42118.44KOct 30, 2024
Fidelity Series Total Market Index Fund0.05%8,14115.93KOct 30, 2024